First Time Loading...

Amgen Inc

Watchlist Manager
Amgen Inc Logo
Amgen Inc
Price: 268.76 USD -0.76% Market Closed
Updated: Oct 1, 2023

Intrinsic Value

Intrinsic Value History
Amgen Inc

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access Amgen Inc's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis


Balance Sheet Decomposition
Amgen Inc

Current Assets 47.4B
Cash & Short-Term Investments 34.2B
Receivables 5.8B
Other Current Assets 7.3B
Non-Current Assets 42.9B
PP&E 5.5B
Intangibles 30.2B
Other Non-Current Assets 7.2B
Current Liabilities 17.1B
Accounts Payable 1.2B
Accrued Liabilities 13.7B
Other Current Liabilities 2.2B
Non-Current Liabilities 66.4B
Long-Term Debt 59.4B
Other Non-Current Liabilities 7B
Fundamental Scores

AMGN Profitability Score
Profitability Due Diligence

Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Free Cash Flow
Positive Gross Profit
Exceptional ROE

Amgen Inc's profitability score is 76/100. The higher the profitability score, the more profitable the company is.

AMGN Solvency Score
Solvency Due Diligence

Amgen Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Average Interest Coverage

Amgen Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AMGN Price Targets Summary
Amgen Inc

Wall Street analysts forecast AMGN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AMGN is 260.25 USD with a low forecast of 176.75 USD and a high forecast of 325.5 USD.

Price Target
176.75 USD
34% Downside
Price Target
260.25 USD
3% Downside
Price Target
325.5 USD
21% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape


AMGN Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AMGN Return Decomposition
Main factors of price return

What is price return decomposition?

AMGN Price
Amgen Inc

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return 5.61%
Standard Deviation of Annual Returns 16.05%
Max Drawdown -25%
Shares Statistics
Market Capitalization 144B USD
Shares Outstanding 538 000 000
Percentage of Shares Shorted 1.16%


Last Video News
Amgen Inc

Other Videos

Last Important Events
Amgen Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.


Sentiment Analysis
Amgen Inc

Last 7 Days
Last 30 Days
Last 90 Days

Company Profile

Amgen Inc Logo
Amgen Inc


United States of America



Market Cap

144B USD

Dividend Yield



Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 24,200 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company operates in human therapeutics segment. Its marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The firm focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.


Thousand Oaks
1 Amgen Center Dr




24 200


Chairman, CEO & Pres
Mr. Robert A. Bradway
Exec. VP & CFO
Mr. Peter H. Griffith
Exec. VP of Operations
Mr. Esteban Santos
Exec. VP of R&D
Dr. David M. Reese M.D.
Exec. VP of Global Commercial Operations
Mr. Murdo Gordon
VP of Fin. & Chief Accounting Officer
Ms. Linda H. Louie
Show More
Sr. VP & Chief Information Officer
Mr. Mike Zahigian
VP of Investor Relations
Mr. Arvind Sood
Exec. VP, Gen. Counsel & Sec.
Mr. Jonathan P. Graham
Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer
Ms. Nancy A. Grygiel
Show Less

See Also

Other Stocks
What is the Intrinsic Value of one AMGN stock?

The intrinsic value of one AMGN stock under the Base Case scenario is 200.3 USD.

Is AMGN stock undervalued or overvalued?

Compared to the current market price of 268.76 USD, Amgen Inc is Overvalued by 25%.